Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 1

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 1
---
; 2,853 shares authorized; 60 and 2,853 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively; liquidation preference of $60,000 at June 30, 2025 
     46,935  
     1,249,999 
  
    Series D convertible preferred stock, $0.0001 par value; 12,500 shares
authorized; 9,503 and 0 issued and outstanding at June 30, 2025 and December 31, 2024, respectively; liquidation preference of $11,687,500
at June 30, 2025 
     7,240,180  
     - 
  
    Series A convertible preferred stock, $0.0001 par value; 12,580 shares authorized; 1,429 and 1,894 issued and outstanding at June 30, 2025 and December 31, 2024, respectively; liquidation preference of $1,429,000 at June 30, 2025 
     1,287,315  
     1,708,396 
  
    Series B convertible preferred stock, $0.0001 par value; 626 shares authorized; 0 and 273 issued and outstanding at June 30, 2025 and December 31, 2024, respectively; No liquidation preference at June 30, 2025 
     -  
     218,051 
  
    Class A common stock; $0.0001 par value; 1,000,000,000 shares authorized; 1,194,802 and 120,794 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 
     119  
     12 
  
    Additional paid-in capital 
     71,311,399  
     67,142,276 
  
    Stock subscription receivable 
     (78,750) 
     (1,295,444)
  
    Accumulated deficit 
     (81,441,099) 
     (70,917,853)
  
    Total stockholders’ deficit 
     (1,633,901) 
     (1,894,563)
  
    Total liabilities and stockholders’ deficit 
    $6,